AIDX
20/20 Biolabs, Inc.Company Information
- Company Name
- 20/20 Biolabs, Inc.
- CIK
- CIK0001139685
- Category
- <br>Emerging growth company
- Ticker: Exchange
- AIDX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 08 Industrial Applications and Services
- SIC
- 8734
- SIC Description
- Services-Testing Laboratories
- Ticker
- AIDX
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- —
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 300,425
- Shares outstanding
- 7,657,229
- Ownership
- 3.92%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 7.27%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Series E Convertible Preferred Stock | 0 | 0 | - | ||||||
| Series D Preferred Stock | 0 | 0 | 0 | ||||||
| Series C Preferred Stock | - | 0 | 0 | ||||||
| Series B Preferred Stock | - | 0 | 0 | ||||||
| Series A2 Preferred Stock | - | 0 | 0 | ||||||
| Series A1 Preferred Stock | - | 0 | 0 | ||||||
| Series A Preferred Stock | 0 | 0 | 0 | ||||||
Assets Current | |||||||||
| Cash And Cash Equivalents At Carrying Value | 5 | 4 | 1 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | ||||||
| Inventory Net | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | ||||||
| Assets Current | 5 | 5 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | ||||||
| Deferred Costs | - | - | 2 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | ||||||
| Assets | 6 | 6 | 4 | ||||||
Liabilities Current | |||||||||
| Accounts Payable Current | 1 | 1 | 1 | ||||||
| Accrued Liabilities Current | 1 | 1 | 1 | ||||||
| Dividends Payable Current | 0 | 0 | - | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | ||||||
| Derivative Liabilities Current | - | - | 0 | ||||||
| Convertible Notes Payable Current | - | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | ||||||
| Liabilities Current | 3 | 3 | 2 | ||||||
Liabilities Noncurrent | |||||||||
| Convertible Long Term Notes Payable | - | - | 1 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | 1 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | ||||||
| Liabilities Noncurrent | 0 | 0 | 2 | ||||||
| Liabilities | 3 | 3 | 4 | ||||||
Stockholders Equity | |||||||||
| Common Stock Value | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 38 | 38 | 33 | ||||||
| Retained Earnings Accumulated Deficit | -37 | -35 | -33 | ||||||
| Stockholders Equity | 2 | 3 | -0 | ||||||
| Liabilities And Stockholders Equity | 6 | 6 | 4 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 12 | 10 | 5 | ||||||
| Shares Outstanding | 12 | 10 | 5 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trial20/20 Biolabs, Inc. (AIDX) — SEC Financial Statements & Analysis
20/20 Biolabs, Inc. (AIDX) is a services-testing laboratories company, incorporated in DE. 20/20 Biolabs, Inc. trades on Nasdaq as: AIDX. 20/20 Biolabs, Inc. (AIDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, 20/20 Biolabs, Inc. carries a market cap of $5.93M, a P/B ratio of 3.66x, and an enterprise value of $1.39M. On the balance sheet, it maintains a current ratio of 1.99x, a quick ratio of 1.90x, working capital of $2.52M, a debt-to-equity ratio of 1.83x, a debt ratio of 0.48, and net debt of $-4.55M. Figures sourced from SEC EDGAR.
- Market Cap
- $5.93M
- P/B TTM
- 3.66x
- Debt To Equity
- 1.83x
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is 20/20 Biolabs, Inc. in?
20/20 Biolabs, Inc. (AIDX) operates in the Services-Testing Laboratories industry.
What exchange does AIDX trade on?
20/20 Biolabs, Inc. (AIDX) trades on the Nasdaq.
Where is 20/20 Biolabs, Inc. incorporated?
20/20 Biolabs, Inc. is incorporated in DE.
When was 20/20 Biolabs, Inc. (AIDX)'s most recent SEC filing?
20/20 Biolabs, Inc. (AIDX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is AIDX's market cap?
20/20 Biolabs, Inc. (AIDX) has a market capitalization of $5.93M as of 2026-06-30.